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Abstract
Background: Neuroblastoma (NB) is one of the most common childhood malignancies. Currently, high risk NB
carries a poor outcome and significant treatment related toxicities and, thus has been a focus for new therapeutics
research in pediatric oncology. In this study, we evaluated the effects of the MEK inhibitor cobimetinib, as a single
agent and in combinations, on the growth, survival and differentiation properties against a molecularly
representative panel of NB cell lines.
Methods: In vitro anti-proliferative activity of cobimetinib alone or in combination was investigated by cell viability
assays and its target modulatory activity was evaluated using phospho-kinases antibody arrays and western blot
analysis. To determine the effect of combination with cis-RA on differentiation and resulting enhanced cellular
cytotoxicity, the expression of glial fibrillary acidic protein (GFAP) and microtubule-associated protein 2 (MAP2)
expression levels were examined by immuno-fluorescence.
Results: Our findings show that cobimetinib alone induced a concentration-dependent loss of cell viability in all NB
cell lines. In addition, cobimetinib showed feedback activation of MEK1/2, and the dephosphorylation of
extracellular signal-regulated kinases (ERK1/2) and c-RAF, providing information on the biological correlates of MEK
inhibition in NB. Combined treatment with cis-RA, led to differentiation and enhanced sensitization of NB cells lines
to cobimetinib.
Conclusion: Collectively, our results provide evidence that cobimetinib, in combination with cis-RA, represents a
feasible option to develop novel treatment strategies for refractory NB.
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Background
Neuroblastoma (NB) is a malignancy of the embryonal
sympathetic nervous system arising from neuroblasts
and is the most common type of solid tumors in chil-
dren [1]. Although cure rates have improved over the
past 20 years, event-free survival is still only about
45 % for patients with high-risk metastatic disease [2].
Heterogeneity is the hallmark of NB and its clinical
behavior ranges from spontaneous regression to meta-
static disease that is refractory to common therapies.
Advanced NB typically metastasizes to regional lymph
nodes, bone marrow, skin and liver [3]. Distinct prog-
nostic stages (1, 2A, 2B, 3, 4 and 4S) have been identified
for the classification of NB [4]. The best-characterized
genetic alterations of NB include N-Myc oncogene- amp-
lification or allelic loss, near triploid karyotype, deletion of
short arm of chromosome 1, chromosomal rearrange-
ments involving chromosome 11q and high expression of
tropomyosin receptor kinase A (TrkA) and B (TrkB). To
improve the clinical outcome of advanced NB, it is
important to identify the key molecularly defined action-
able pathways and targets for novel therapeutics in these
patients.
The Mitogen-activated protein kinases (MAPKs) cascade
(Ras/Raf/MEK/ERK) is an important signal transduction
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system involved in the control of cell proliferation, survival
and differentiation [5]. A wide range of cell-surface mole-
cules activate RAS (KRAS, NRAS, and HRAS), a family of
GTPases, that act as a molecular switch in the activation of
MAPKs cascade (Raf/MEK/ERK) [6]. There are multiple
molecular mechanisms of interaction and activation
between the upstream nodes of the Ras/Raf/MEK/ERK
cascade and other cell signaling pathways, ultimately
resulting in ERK transcription factor activation [7].
The activation of ERK leads to cells acquiring many of
the hallmarks of cancer such as cell survival, cell
migration, and invasion and inhibitors targeting this
pathway have been vigorously developed [8, 9]. The
MEK inhibitors act on MEK phosphorylation by bind-
ing to a pocket adjacent to the ATP binding site,
decreasing both the amount of MEK activity, and the
quantity of activated ERK in the cell. Cobimetinib is a
potent and highly selective inhibitor of MEK1 [10].
In this study, we evaluated the expression and activity
of MEK and ERK in a panel of NB tumor cell lines and
their sensitivity to cobimetinib in vitro. The panel of cell
lines used included the neuroblastic (N), substrate-adherent
(S), and intermediate (I) subtypes, classified based on their
morphology, growth patterns, and malignant potential [11].
In addition, in drug combination studies we have also
tested the ability of cis-retinoic acid (cis-RA) that has been
known to cause cell growth inhibition and differentiation
[12], to enhance the activity of cobimetinib against NB cells.
Our data provide initial proof-of-concept information on
the potential utility of cobimetinib as an effective targeted
therapeutic agent against refractory NB.
Materials and methods
Cell lines and cell culture
The following NB cell lines were used: SK-N-AS (AT
CC-CRL-2137), SK-N-SH (ATCC HTB-11), SK-N-BE(2)
(ATCC CRL- 2271), IMR-32 (ATCC CCL-127), SHEP,
IMR-5. SHEP and IMR-5 cell lines were a gift from Dr.
Herman Yeger (The hospital for Sick Children, Toronto,
ON). These cells were maintained in Opti-MEM media
(Gibco, Invitrogen Corporation, Burlington, ON) supple-
mented with 5 % fetal bovine serum and 100 units/ml
penicillin and 100 units/ml streptomycin (Gibco). Con-
fluent cells were trypsinized with 0.25 % Trypsin-EDTA
in Ca2+ and Mg2+ free balanced salt solution (Gibco)
every three to five days. All cell cultures were main-
tained in incubators at 37 °C in a humidified atmosphere
with 5 % CO2.
The MEK inhibitor cobimetinib (GDC-0973) was kindly
provided by Roche (Basel, Switzerland).
Stock solutions of cobimetinib were prepared as 10 mM
in DMSO and stored in aliquots at −20 °C. Cis-RA was
obtained from Sigma (Oakville, ON).
Drug cytotoxicity assays
Neuroblastoma cells were trypsinized and placed in 96
well plates (Grenier Bio One, Monroe, NC) at a concen-
tration of 5 x 103 cells per well. Increasing concentra-
tions of study agents and a corresponding dilution of
DMSO were added to a final volume of 200 μl per well.
After four days in culture, cell survival was quantified by
an inverted microscope (Cyntellect Inc, San Diego, CA;
http://www.nexcelom.com/Celigo/direct-cell-counting-as-
says-for-immunotherapy.php#feature6). The half maximal
inhibitory concentration (IC50) values were calculated for
each agent based on individual cytotoxicity plots.
Human phospho-kinase antibody array
Neuroblastoma cells were seeded in six well culture
plates (Nunc, Waltham, MA) at 1 x 106 cells/ml and in-
cubated overnight. Fresh culture medium containing
cobimetinib or vehicle control was added and after two
hour incubation, cells were washed with ice cold PBS
and treated with lysis buffer (50 mM Tris, 5 mM EDTA,
0.1 % SDS, 1 % Triton X-100, 0.5 % sodium deoxycho-
late) containing phosphatase and protease inhibitors
(Sigma). Human phopsho-kinase array (R&D Systems,
Inc., Minneapolis, MN) were incubated with cobimetinib-
treated and control cell lysates (150 μg) over-night,
washed and probed with horseradish peroxidase (HRPO)
(Sigma) labeled anti-pTyr antibodies according to manu-
facturer’s protocol. The arrays were scanned and the spot
densities were quantified with ImageJ (National Institutes
of Health, http://rsb.info.nih.gov/ij/ version 1.4.3.67).
Western blot analysis for protein and phosphoprotein
detection
Each NB cell line was grown to 70 to 80 % confluence in
six well culture plates (Nunc) and incubated overnight
to allow for cell adherence. The cells were then incu-
bated with fresh culture medium containing cobimetinib
or vehicle control as indicated in individual experiments.
After each time period incubation, cells were washed
with ice cold PBS and treated with lysis buffer contain-
ing phosphatase and protease inhibitors. Protein concen-
trations of the lysates were quantified by BCA Protein
Assay (Pierce, Rockford, IL). Proteins were then sepa-
rated on a 8 % polyacrylamide gel electrophoresis and
transferred onto nitrocellulose (NC) membranes (Bio-
Rad, Mississauga, ON). The membranes were blocked
for one hour at room temperature with 5 % skim milk
powder in PBS containing 0.1 % Tween-20 (Sigma).
The blots were incubated with primary antibodies (Cell
Signaling Technology, Danvers, MA) overnight at 4 °C,
washed and probed with appropriate secondary anti-
bodies conjugated to horseradish peroxidase (HRPO)
(Sigma), followed by a luminal based substrate (Mandel,
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Guelph, ON) and developed by exposure to x-ray film
(Fisher Scientific, Ottawa, ON).
Annexin V staining for apoptosis
Neuroblastoma cell lines (IMR-32, SHEP and IMR-5)
were plated at a concentration of 3 × 105 cells per well.
Following treatment with 1 μM cobimetinib or DMSO
(vehicle control) the cells were incubated for a period of
24 hour prior to FACS analysis. Apoptosis was measured
using the Annexin V-FITC Apoptosis Detection kit (Life
Technologies, Carlsbad, CA) according to the manufac-
turer’s instructions. In this assay, the apoptotic cells were
differentiated from viable or necrotic cells by the com-
bined application of Annexin V-FITC and propidium
iodide (PI). Briefly, the control and treated cells (1 × 106)
were re-suspended in 500 μl of binding buffer and incu-
bated with 5 μl of Annexin V-FITC and 1 μl of PI solu-
tion for 15 min. The samples were then analyzed on a
BD Facscan Instrument (BD Biosciences, Franklin
Lakes, NJ), measuring the Annexin V-FITC emission
at 488 nm and PI emission at 575 nm. Lower right
quadrant (Q4) represent percentage of early apoptotic
cells out of total cell population in the treatment
group compared to control.
Treatment with cis-RA
Cis-Retinoic acid was added to a final concentration of
10 μM, according to feasible pharmacological dosages
and those used in previous in vitro differentiation studies
[13, 14]. To see the combined effect of cis-RA and cobi-
metinib on cell growth inhibition, IC25 concentration of
cobimetinib (i.e., the amount that induced 25 % cell
death in single drug studies) was added to cultures con-
taining increasing concentrations of cis-RA. The number
of viable cells present after four days in culture was
determined as described.
Immunocytochemical detection of differentiation markers
Neuroblastoma cells were treated with cobimetinib
(1 μM) and cis-RA (10 μM) alone or in combination
for 24 hours. Briefly, the cells were fixed with 4 %
paraformaldehyde (Sigma) and permeabilized with
0.05 % Triton X-100 (Sigma). The cells were incubated
with antibodies to Nestin (R&D Systems, 1:1000),
GFAP (Sigma, 1:1000) and MAP-2 (Sigma, 1:800) for
two hours at 37 °C. The cells were then washed with
PBS and incubated with fluorescence labelled second-
ary antibody (Invitrogen, 1:500) at room temperature
for one hour. Staining of treated and untreated cells
were then visualized by fluorescence microscopy for
detection of differentiation markers.
Statistical analysis
For 2-group comparisons, Student t tests using the
GraphPad Prism software (version 4.0) were used. The
results are considered statistically significant versus the
untreated cells, with a probability level of p < 0.05 (*), or
statistically highly significant with a probability level of
p < 0.01 (**).
Results
In order to evaluate the cytotoxic effects of cobimetinib
against NB, cells from a panel of cell lines were incu-
bated with increasing concentrations of cobimetinib.
After four days in culture, cell viability was evaluated.
Results presented in Fig. 1 show that cell line IMR-32 is
highly sensitive to cobimetinib with IC50 of 0.07 μM and
IMR-5 was least sensitive for cobimetinib showing activ-
ity at 10 μM. Other NB cell lines fell in between this
range of IC50 values showing an intermediate activity. In
the next set of experiments, the activation status of MEK
was evaluated by western blot analysis under serum con-
taining and serum free culture conditions. Findings from
these experiments show that cells with increased phos-
phorylated MEK were more sensitive to cobimetinib com-
pared to those with less MEK1/2 phosphorylation (Fig. 2).
There was no significant difference in MEK1/2 activity
between cells grown with serum and without serum sug-
gesting that the growth factors found in serum do not
have significant influence in the base-line MEK activity
found in these cells in culture.
Next, we wanted to evaluate the target modulatory
activity of cobimetinib in NB cells. Antibody arrays to a
panel of signaling molecules were used to screen for
phosphorylation effects by cobimetinib. Proteins were
extracted from cells treated with 1 μM of cobimetinib
and cell lysates were made with lysis buffer containing
protease and phosphatase inhibitors. DMSO treated cells
were used as control. Antibody arrays were incubated
with 200 μg of proteins over night at 4 °C with gentle
mixing and probed with HRPO conjugated anti-phospho
antibodies. Figure 3a provides a map of the positions of
the various kinases on the arrays used. Figure 3b shows
changes in phosphorylation as seen by gain or loss of
signal on the x-ray film. A waterfall graph showing the
change in optical density of array spots of cobimetinib
treated cells compared to control DMSO treated cells is
given in Fig. 3c. As can be seen in these figures, there is
a gain in MEK phosphorylation whereas a loss in phos-
phorylation was noticed in ERK1/2. In addition, c-Jun
also showed a gain in phosphorylation while a decrease
in phosphorylation was noted with RSK1/2/3.
The antibody array findings were then confirmed using
western blot analysis (Fig. 4). Three NB cell lines IMR-32,
SHEP and IMR-5 representing sensitive, intermediate and
resistant cell toxicity against cobimetinib respectively were
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used for western blot analysis. The NB cell lines were incu-
bated with cobimetinib (1 μM) or corresponding DMSO
controls for four hours, harvested and subjected to western
blotting. Results showed cobimetinib treatment induced
de-phosphorylation of c-RAF and ERK and an increase in
the phosphorylation of MEK.
The drug sensitivity studies provided evidence for
cobimetinib induced reduction in viable cell numbers
after exposure. To further evaluate the potential role
of apoptosis in this process, we examined PARP cleav-
age induced by cobimetinib (Fig. 5). Neuroblastoma
cell lines IMR-32, SHEP and IMR-5 were incubated in
the absence or presence of cobimetinib (1 μM) for
24 hour and cell lysates were analyzed by western blot.
IMR-32 and SHEP showed PARP cleavage as indica-
tion of apoptosis induction. To further confirm this
finding an Annexin V/PI binding assay was performed
(Fig. 6a and b). Our data revealed an increased per-
centage of early apoptotic cells (Annexin V+/PI−) after
treatment of IMR-32 and IMR-5 cells with cobimeti-
nib for 24 h. There was no significant difference in the
percentage of early apoptotic cells between the control
group and the SHEP cell line.
Next, studies were carried out to examine time
dependent changes induced by cobimetinib with re-
spect to some of the changes in growth regulatory
pathways detected in the western blot analysis (Fig. 7a).
In these experiments, IMR-32 Cells were harvested
Fig. 1 Cobimetinib mediated cytotoxicity against NB cells. Triplicate wells of cells from six NB cell lines were treated with increasing
concentrations of cobimetinib or corresponding concentrations of vehicle control (DMSO) and cell viability was evaluated after four days
in culture using automated microscopy. Results presented show cell growth inhibition compared to DMSO control. Data presented are
representative of three separate experiments
Fig. 2 Constitutive phosphorylation status of MEK in NB cells: NB cells were grown in serum containing and serum free media and collected at
their exponential growth phase (three days after sub-culture). These cells were lysed in buffer containing protease and phosphatase inhibitors
and probed for total and phosphorylated MEK by western blot analysis. Data presented are representative of three separate experiments
Singh et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:104 Page 4 of 13
AB
C
Fig. 3 (See legend on next page.)
Singh et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:104 Page 5 of 13
after treatment with or without 1 μM cobimetinib for
the indicated periods. The activation of MEK1/2 was
noticed as earlier as five minute after treatment. Data
from similar analysis on IMR-5 and SHEP are pre-
sented in Fig. 7b and c respectively. Both SHEP and
IMR-5 cell lines showed increase of MEK1/2 phos-
phorylation in the indicated time period.
In the following experiments, we investigated the poten-
tial of cis-RA to enhance the activity of cobimetinib in drug
combination. Neuroblastoma cells were incubated with
increasing concentrations of cis-RA plus IC25 concentration
of cobimetinib. The IC25 values used were 2 μM, 0.07 μM
and 0.04 μM for IMR-5, SHEP and IMR-32 respectively.
Data presented in Fig. 8a-c indicate that, under the specific
experimental conditions used, cis-RA in combination with
cobimetinib showed a significant decrease in cell growth in
all cell lines tested compared to the drug alone. Next, we
explored the induction of differentiation as a potential
mechanism in the enhanced activity seen in this
combination. For this purpose, the involvement of
cells expressing the differentiation markers, GFAP and
MAP2 were analyzed using immuno-fluorescence. As
can be seen in Fig. 9, there was an increase in GFAP
(9A) and MAP2 (9B) expression in cells treated with
cobimetinib and cis-RA alone or in combination, com-
pared to control. These data suggest that cobimetinib
alone was also able to induce differentiation, which
was enhanced after combined treatment with cis-RA.
We also tested Nestin to validate differentiation re-
sults and noticed a decrease in Nestin expression after
the treatment alone or in combination (Fig. 9c).
Discussion
Neuroblastoma is the most common extracranial solid
tumor in the pediatric population and currently, the
treatment of high-risk NB with multi-modal thera-
peutic approaches still results in less than 50 % 5-year
event-free survival [15]. Hence, there is a significant
Fig. 4 Effect of cobimetinib on MAPK cascade pathway. Changes in activation status of RAF, MEK and ERK were evaluated in three NB cell lines
after treatment with cobimetinib (1 μM) or DMSO for four hours. Cell lysates were made with lysis buffer containing protease and phosphatase
inhibitors and probed for total and phospho specific antibodies by western blot analysis. Data presented is representative of three
separate experiments
(See figure on previous page.)
Fig. 3 Identification of potential targets of cobimetinib activity on NB cells. Antibody arrays to a panel of signaling molecules were used to
screen for dephosphorylation effects by cobimetinib. Proteins were extracted from IMR-32 cells treated with 1 μM of cobimetinib and cell lysates
were made with lysis buffer containing protease and phosphatase inhibitors. DMSO treated cells were used as control. Antibody arrays were
incubated with 200 μg of proteins over night at 4 °C with gentle mixing and probed with HRPO conjugated anti-phospho Tyr/Ser/Thr antibodies
as per manufacturer’s protocol. Presented is the map of the orientation of the antibodies on the array (a), luminographically developed blots of
cobimetinib treated and DMSO treated blots (b) and the waterfall plot showing changes in phosphorylation status of each signaling molecule on
the arrays (c). Findings were representative of two completely separate experiments
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and urgent need to develop mechanism based novel
therapeutic approaches and early phase clinical trials
for the treatment of patients with refractory and high-
risk disease. Recently, targeting key receptor tyrosine
kinases and their downstream signaling mediators has
been shown to be an effective approach in new therap-
ies development in a number of cancer models. In NB,
abnormal activation of a number of receptor tyrosine
kinases (RTKs) has been reported. These include insu-
lin growth factor 1 (IGF1), c-Kit and the Trk family of
receptors. However, as NB cells appear to be highly
heterogeneous in the expression of active RTKs, it
remains unknown if the targeting individual RTKs
would be and an efficient approach. For this reason, the
identification of inhibitors for critical downstream sig-
naling nodes that are involved in the transmission of
abnormal survival, proliferation and differentiation sig-
nals from affected RTKs has been suggested as a poten-
tially viable alternative [16].
The MAPK signaling pathway has been shown to play a
critical role in the transmission and coordination of diverse
extracellular and environmental stimuli to cell growth
mechanisms and MAPK pathway dysregulation has been
demonstrated in a variety of human malignancies [17].
Fig. 5 PARP cleavage induced by cobimetinib. Neuroblastoma cell lines IMR-32, SHEP and IMR-5 were incubated in the absence or presence of
cobimetinib (1 μM) for 24 hour and cell lysates were analyzed by western blotting using antibodies specific for PARP and its cleaved fragment.
Actin was used as loading control. Data presented is representative of two separate experiments
A B
Fig. 6 The flow cytometric analysis of apoptosis in NB cells using FITC-annexin V and PI double staining. (a) Apoptosis was evaluated after treating NB
cells with 1 μM of cobimetinib for 24 hour, and staining with Annexin-V. Annexin V+/PI− (lower right quadrant) areas represent early apoptotic cells,
and Annexin V+/PI+ (upper right quadrant) areas for late apoptotic or necrotic cells. (b). Quantitative analysis of the percentage of early apoptotic cells
in all NB cell lines. Data presented is representative of two separate experiments
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MEK1 is a dual-specificity tyrosine threonine protein kinase
that occupies a central node in the MAPK signaling path-
way [18]. MEK1 phosphorylates ERK1 (p44 MAPK)
and ERK2 (p42 MAPK ) to activate pathways that
regulate the proliferation and differentiation in cancer
cells [19]. A number of previous studies have shown
the important role of MEK1 in NB tumorigenesis. For
example, in the NB cell line KP-N-RT, IGF-1 leads to
phosphorylation of ERK and that the specific MEK1
inhibitor PD98059 leads to the inhibition of IGF-1 me-
diated cell cycle progression [20]. In this report we aim
to investigate the effects of cobimetinib, a potent, orally bio-
available, small-molecule inhibitor of MEK1, against a panel
of NB cell lines in order to investigate its feasibility in future
therapeutic interventions. Cytotoxicity data presented in
Fig. 1 shows effective cell killing, as determined by IC50
values, of SK-N-BE(2), SHEP and IMR-32 cells and inter-
mediate activity against SK-N-AS and SK-N-SH cells. The
IMR-5 cells appear to be resistant under our experi-
mental conditions. Previously, Eppstein and colleagues
have investigated the effects of the MEK inhibitor
U0126 against three NB cell lines representing the
three types of cells; SK-N-AS (S-type), SH-SY5Y (N-
type) and BE(2)-C (I-type) [21]. Their findings showed
that although all three cell lines exhibit decrease in
pERK with MEK inhibition only the I type cell BE(2)–
C had decreased proliferation showing heterogeneity
in MEK mediated growth inhibition. Next, we exam-
ined the levels of constitutive pMEK in each cell line




Fig. 7 Time course analysis of cobimetinib on MAPK cascade pathway: Cells from three NB cell lines (IMR-32 (a), IMR-5 (b) and SHEP (c)) were
harvested after treatment with 1 μM cobimetinib or DMSO control for the indicated periods. Cells were then lysed in protease and phosphatase
containing buffer and probed for total and phosphorylated MEK by western blot analysis. Data presented is representative of three
separate experiments
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their response to cobimetinib (Fig. 2). Interestingly, the
IMR-5 cells that appear to have the lowest amounts of
pMEK also appear to be resistant to growth inhibition
by cobimetinib. This indicates the potential of using
constitutive activation status of MEK1 as a biomarker
for efficacy in treatment protocols using cobimetinib.
However, due to the limited sample size of the cell lines
used, studies using a larger cell line panel and/or primary
samples are needed to confirm this utility.
To further expand the target modulatory effects of
cobimetinib in NB cells, we used antibody arrays to
identify changes in various intracellular signaling mole-
cules (Fig. 3). As expected, there is an increase in MEK
and decrease in ERK activity was noted. However, we
also detected an increase in c-Jun, which is normally a
target of ERK activity, and a decrease in the activity of
RSK 1/2/3. The RSK family of proteins function down-
stream of ERK and are considered to be an important
conveyer of ERK signaling [22]. In addition we also ex-
amined changes in c-RAF, MEK and ERK status in rela-
tion to their sensitivity to cobimetinib by evaluating the
levels of activation in IMR-32 (sensitive), SHEP (inter-
mediate) and IMR-5 (resistant) cells (Fig. 4). From these
data we observed that the dephosphorylation pattern of
c-RAF corresponds well with cell growth inhibition as it
is most prominent in IMR-32 and next SHEP cells with
IMR-5 showing no change. A similar pattern is also seen
with ERK activity. However, conversely, IMR-32 cells
showed the most increase in MEK activation indicating
a consistent pattern of intracellular target modulation
and inhibition of proliferation by cobimetinib in distinct
NB cell lines. Previously, using the proteomic profiling
approach, the potential biological pathways that may
confer sensitivity to MEK inhibition in NB subtypes have
been investigated by Sandoval and colleagues [23]. Their
data suggested that the inhibition of MEK leads to differ-
ential intracellular stress response in different NB sub-
types and the most resistant cell lines generated unique
patterns in protein profiling indicating the utility of
these proteins as biomarkers for therapeutic response. In
our studies PARP cleavage data provides a biomarker of
apoptosis that corresponds to the activity of cobimetinib
against the three NB subtypes (Fig. 5). In FACS analysis,
cobimetinib treatment has also shown an increased in
the number of early apoptotic cells in the IMR-32 and
IMR-5 cell line after 24 hour treatment (Fig. 6). We also
found that although all three cell lines generated pMEK
in response to cobimetinib treatment, the resistant cell
line IMR-5 also took the longest time to show this re-
sponse (30 min to 2 hours), compared to the sensitive
cell lines (5 min) (Fig. 7). These data provide dosing and
scheduling guidelines for future studies to further inves-
tigate the activity of cobimetinib in vivo.
Our initial cytotoxicity and target modulation studies
described above suggested potential antitumor activity of
cobimetinib against the NB cells although there is a
range in the sensitivity exhibited by different cell lines.
In order to optimize the utility of cobimetinib across all
NB subtypes and to enhance the overall effectiveness in
future therapeutic regimens, we then explored possible
drug combinations that can further enhance the overall
effectiveness of cobimetinib against NB. Previous studies
have shown that treatment of NB cells with retinoic acid
leads to differentiation, cell growth arrest and the de-
crease in MYCN expression [24]. Cis-RA has also been
found to provide survival advantage in combination with
immunotherapy with anti-GD2 antibody, combined with
GM-CSF or IL-2 [25]. It has been suggested that RA
combination with other drugs may lead to synergistic
effects allowing the potential to deliver RA at low con-
centrations to minimize non-specific side effects [24].
Based on this premise we explored the ability of cis-RA
to enhance the activity of cobimetinib against the NB
cell lines. Interestingly, this combination resulted in in-
creased cell killing in all three cell lines (Fig. 8). Further-
more, morphological and immunohistochemical analysis
of the three cell lines treated with this combination
showed evidence for morphological differentiation and
the expression of markers involved in this process. Un-
expectedly we also found that cobimetinib itself is capable
of inducing differentiation in NB cells. At present, min-
imal residual disease is prevented by repeated courses of
the RA treatment; however this treatment only improves
survival by 35 % in children with metastatic neuroblast-
oma [26]. In neuroblastoma cell differentiation, cobimeti-
nib alone showed less potency; however, cobimetinib was
found to enhance the differentiation induced by RA,
suggesting that these compounds could interact coopera-
tively to improve the NB differentiation and cell killing
(Fig. 9). Studies are currently in progress to identify the
mechanism of this effect, particularly to understand the
influence MEK targeting agents in NB differentiation.
(See figure on previous page.)
Fig. 8 Drug combination studies of cobimetinib with cis-RA in NB cell lines: NB cells were incubated with 1 μM of cis-RA acid plus IC25 concentration
of cobimetinib for each cell line as obtained from Fig. 1. The IC25 values used were 2 μM, 0.07 μM and 0.04 μM for IMR-5, SHEP and IMR-32 respectively.
Data shown indicate percent survival with each drug or in combination compared to corresponding DMSO treatment. Cultures were set up in
triplicate and the data presented are representative of two separate experiments. P values indicate statistical significance. Figures a, b, and c show
findings from the cell lines IMR-32, IMR-5 and SHEP respectively
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Conclusion
Taken together, our in vitro findings from a panel of NB
cell lines suggest that the targeted inhibition of MEK1
by cobimetinib holds the potential to induce potent anti-
tumor activity although there are subsets of cells that
may be affected by this treatment. We have also pro-
vided key biological markers for this activity that can be
used to identify the patient population that may benefit
the most by this treatment, Furthermore we also provide
evidence for an effective combination of cobimetinib
with cis-RA would to enhance antitumor activity in all
NB cells. Additional in vivo studies in NB xenograft are
needed to confirm and further develop these finding for
the formulation of effective early phase clinical trials for
the treatment of refractory NB patients in the future.
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